Survodutide

Survodutide is a dual GLP-1/glucagon receptor agonist with Phase 2 clinical trial evidence supporting its mechanisms in humans.

How It Works (Simplified)

Survodutide acts as a “dual signal” metabolic regulator through complementary pathways:

Key Research: Sanyal AJ et al. (NEJM, 2024) reported MASH improvement without worsening of fibrosis in up to 62% of survodutide-treated participants (4.8mg dose) vs 14% on placebo in a 48-week Phase 2 trial. PMID:38847460

SYNCHRONIZE-1 — the phase 3 obesity result

SYNCHRONIZE-1, published in the New England Journal of Medicine on 7 June 2026, is the phase 3 obesity trial (PMID:42253238, NCT06066515). It randomised 725 adults with a BMI of 30 or above, or 27 or above with an obesity-related complication and without diabetes, 1:1:1 to once-weekly survodutide adjusted up to 3.6 mg, up to 6.0 mg, or placebo, for 76 weeks alongside lifestyle counselling. Mean baseline BMI was 37.9.

The paper states its estimand choice explicitly, and it is the strict one: the primary efficacy analysis used the treatment-regimen estimand, which incorporates early discontinuation, use of prohibited obesity medications and prolonged escalation. Mean body-weight change at week 76 was -12.2% (95% CI -13.6 to -10.8) at 3.6 mg and -13.0% (95% CI -14.4 to -11.6) at 6.0 mg, against -5.4% (95% CI -6.9 to -4.0) on placebo. At least 5% weight reduction was reached by 72.6%, 71.9% and 46.3% respectively.

Two features deserve attention. The placebo arm lost 5.4%, which is high for an obesity trial and narrows the placebo-adjusted gap to roughly 7 to 8 percentage points. And gastrointestinal adverse events reached 80.9% and 89.7% in the survodutide groups against 47.9% on placebo — the higher strength bought little extra weight loss for a good deal more gastrointestinal burden. No deaths were reported.

SYNCHRONIZE-MASLD — the liver result

SYNCHRONIZE-MASLD, published in Nature Medicine on 7 June 2026, is the first phase 3 trial of survodutide to report (PMID:42252333, NCT06309992). It enrolled 216 adults with obesity and at-risk MASLD — defined by liver inflammation or fibrosis on non-invasive tests, or biopsy-confirmed MASH — and randomised them 2:1 to once-weekly subcutaneous survodutide 6.0 mg (n=146) or placebo (n=70) for 48 weeks. Both co-primary endpoints were met.

The paper reports each co-primary endpoint under two estimands, and the difference between them is large:

The treatment-regimen figures are the ones this page leads with. That estimand keeps every randomised participant in the analysis, including those who stopped treatment, so it describes the result of being assigned the drug. The efficacy estimand describes only what happened while participants remained on treatment, which is why its numbers are larger. Both are reported in the paper; neither is wrong, but they answer different questions and are not interchangeable.

The most frequent adverse events with survodutide were gastrointestinal, concentrated during dose escalation and generally mild to moderate. The authors name two limitations directly: the 48-week duration is short for a liver endpoint, and recruitment was confined to the United States and Spain.

The publisher’s author correction (PMID:42642663) amended investigator details, corrected the placebo treatment-discontinuation denominator from 72 to 70, and changed an Extended Data Fig. 5 caption from week 48 to week 52. It did not amend the co-primary effect estimates quoted above; the main article’s HTML and PDF incorporate the correction.

Two named registrations may be noted only, with no results: NCT07754461 (Phase 3 type 2 diabetes, recruiting) and NCT07768813 (Phase 1 formulation comparison, not yet recruiting).

Important Limitations

• SYNCHRONIZE-MASLD, the liver trial, is one 48-week study of 216 participants recruited in two countries. SYNCHRONIZE-2 (NCT06066528) and the cardiovascular outcomes trial (NCT06077864) are both complete, but a dateless PubMed search on 17 August 2026 returned only their design and baseline-characteristics papers, not results
• In SYNCHRONIZE-1 the 6.0 mg strength added roughly 0.8 percentage points of weight loss over 3.6 mg while raising gastrointestinal adverse events from 80.9% to 89.7%
• SYNCHRONIZE-MASLD measured liver fat by MRI-PDFF, a surrogate — it did not test histological MASH resolution or fibrosis outcomes
• Phase 3 trials ongoing; not yet FDA approved for any indication
• Longer-term safety remains under study; SYNCHRONIZE-1 followed participants for 76 weeks, while SYNCHRONIZE-MASLD lasted 48 weeks
• No head-to-head trials vs semaglutide or tirzepatide
• Cardiovascular outcome effects are unknown; a completed registry status is not a results report and no peer-reviewed CVOT result was verified here
• Cross-trial comparisons to other agents are inherently unreliable